Cargando…

Progression patterns and site‐specific responses in advanced gastric cancer patients treated with nivolumab

BACKGROUND: While the efficacy of immune checkpoint inhibitors (ICIs) reportedly varies among metastatic sites and progression patterns (classified as systemic progression [SP] or mixed progression [MP]), the clinical efficacy of ICIs against gastric cancer remains unclear. The response to nivolumab...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kadono, Toru, Iwasa, Satoru, Nagashima, Kengo, Oshima, Kotoe, Yamamoto, Shun, Hirano, Hidekazu, Okita, Natsuko, Shoji, Hirokazu, Honma, Yoshitaka, Takashima, Atsuo, Kato, Ken, Ushijima, Toshikazu, Boku, Narikazu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	RESEARCH ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166927/ https://www.ncbi.nlm.nih.gov/pubmed/36789624 http://dx.doi.org/10.1002/cam4.5689

Ejemplares similares

Influence of precedent drug on the subsequent therapy in the sequence of trifluridine/tipiracil with/out bevacizumab and regorafenib for unresectable or recurrent colorectal cancer
por: Oshima, Kotoe, et al.
Publicado: (2022)

Hyperprogressive disease during nivolumab or irinotecan treatment in patients with advanced gastric cancer
por: Aoki, Masahiko, et al.
Publicado: (2019)

Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab
por: Masuda, Ken, et al.
Publicado: (2019)

Panitumumab-Associated Drug-Induced Immune Thrombocytopenia in a Patient with Colorectal Cancer
por: Takamizawa, Shigemasa, et al.
Publicado: (2021)

Case report: potential treatment of metastatic amphicrine carcinoma of the rectum with FOLFOXIRI chemotherapy
por: Tamura, Nobumasa, et al.
Publicado: (2020)

Clinical outcomes of locally advanced esophageal neuroendocrine carcinoma treated with chemoradiotherapy
por: Honma, Yoshitaka, et al.
Publicado: (2019)

Tumor growth rate during re-challenge chemotherapy with previously used agents as salvage treatment for metastatic colorectal cancer: A retrospective study
por: Ishikawa, Masashi, et al.
Publicado: (2021)

Immune status at pre-treatment impacts on progression-free survival of metastatic colorectal cancer patients treated with first-line chemotherapy
por: Tada, Kohei, et al.
Publicado: (2015)

Induction chemotherapy with docetaxel, cisplatin and fluorouracil followed by concurrent chemoradiotherapy for unresectable sinonasal undifferentiated carcinoma: Two cases of report
por: Watanabe, Sho, et al.
Publicado: (2019)

Esophageal Metastasis from Rectal Cancer Successfully Treated with Fluorouracil-Based Chemotherapy with Bevacizumab: A Case Report and Review of the Literature
por: Watanabe, Sho, et al.
Publicado: (2017)

Clinical impact of c-MET expression and genetic mutational status in colorectal cancer patients after liver resection
por: Shoji, Hirokazu, et al.
Publicado: (2014)

Phase II study of lenvatinib for metastatic colorectal cancer refractory to standard chemotherapy: the LEMON study (NCCH1503)
por: Iwasa, Satoru, et al.
Publicado: (2020)

Association between serum ligands and the skin toxicity of anti-epidermal growth factor receptor antibody in metastatic colorectal cancer
por: Takahashi, Naoki, et al.
Publicado: (2015)

The peripheral immune status of granulocytic myeloid-derived suppressor cells correlates the survival in advanced gastric cancer patients receiving cisplatin-based chemotherapy
por: Shoji, Hirokazu, et al.
Publicado: (2017)

Prognostic role of ERBB2, MET and VEGFA expression in metastatic colorectal cancer patients treated with anti-EGFR antibodies
por: Takahashi, Naoki, et al.
Publicado: (2016)

Serum level of hepatocyte growth factor is a novel marker of predicting the outcome and resistance to the treatment with trastuzumab in HER2-positive patients with metastatic gastric cancer
por: Takahashi, Naoki, et al.
Publicado: (2015)

Targeting myeloid villains in the treatment with immune checkpoint inhibitors in gastrointestinal cancer
por: Kudo-Saito, Chie, et al.
Publicado: (2022)

A Phase I study of pevonedistat plus capecitabine plus oxaliplatin in patients with advanced gastric cancer refractory to platinum (NCCH-1811)
por: Shoji, Hirokazu, et al.
Publicado: (2021)

Relationship between cervical esophageal squamous cell carcinoma and human papilloma virus infection and gene mutations
por: Fukahori, Masaru, et al.
Publicado: (2021)

A multi-institutional observational study evaluating the incidence and the clinicopathological characteristics of NeoRAS wild-type metastatic colorectal cancer
por: Osumi, Hiroki, et al.
Publicado: (2023)

Pattern of disease progression during third-line or later chemotherapy with nivolumab associated with poor prognosis in advanced gastric cancer: a multicenter retrospective study in Japan
por: Aoki, Masahiko, et al.
Publicado: (2022)

Clinicopathological features and prognostic roles of KRAS, BRAF, PIK3CA and NRAS mutations in advanced gastric cancer
por: Takahashi, Naoki, et al.
Publicado: (2014)

Comprehensive characterization of the phosphoproteome of gastric cancer from endoscopic biopsy specimens
por: Abe, Yuichi, et al.
Publicado: (2020)

Temporal dynamics from phosphoproteomics using endoscopic biopsy specimens provides new therapeutic targets in stage IV gastric cancer
por: Hirano, Hidekazu, et al.
Publicado: (2022)

Prognostic factors associated with the transition in treatment methods for brain metastases from colorectal cancer
por: Imaizumi, Jun, et al.
Publicado: (2023)

Biomarkers of reactive resistance and early disease progression during chemotherapy plus bevacizumab treatment for colorectal carcinoma
por: Hayashi, Hidetoshi, et al.
Publicado: (2014)

Prognostic factors of brain metastases from colorectal cancer
por: Imaizumi, Jun, et al.
Publicado: (2019)

Perioperative TAS-118 plus oxaliplatin in patients with locally advanced gastric cancer: APOLLO-11 study
por: Takahari, Daisuke, et al.
Publicado: (2023)

Comparison of model fit and discriminatory ability of M category as defined by the 7th and 8th editions of the tumor‐node‐metastasis classification of colorectal cancer and the 9th edition of the Japanese classification
por: Shida, Dai, et al.
Publicado: (2021)

Clinical outcomes of surgical and imatinib treatment for rectal gastrointestinal stromal tumours: retrospective cohort study
por: Tsukamoto, Shunsuke, et al.
Publicado: (2022)

Geriatric assessment and management with question prompt list using a web-based application for elderly patients with cancer (MAPLE) to communicate ageing-related concerns: J-SUPPORT 2101 study protocol for a multicentre, parallel group, randomised controlled trial
por: Matsuoka, Ayumu, et al.
Publicado: (2022)

Shorter survival in adolescent and young adult patients, compared to adult patients, with stage IV colorectal cancer in Japan
por: Shida, Dai, et al.
Publicado: (2018)

Nutritional and inflammatory measures predict survival of patients with stage IV colorectal cancer
por: Takamizawa, Yasuyuki, et al.
Publicado: (2020)

Efficacy of second-line treatment and prognostic factors in patients with advanced malignant peritoneal mesothelioma: a retrospective study
por: Kitadai, Rui, et al.
Publicado: (2021)

Real-world safety and effectiveness of nivolumab in Japanese patients with unresectable advanced or recurrent gastric/gastroesophageal junction cancer that has progressed after chemotherapy: a postmarketing surveillance study
por: Yamaguchi, Kensei, et al.
Publicado: (2021)

HER2-positive gastric cancer
por: Boku, Narikazu
Publicado: (2013)

Second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab for patients with metastatic colorectal cancer
por: Yamamoto, Shun, et al.
Publicado: (2021)

Identifying Early Predictive Markers for Immune-Related Adverse Events in Nivolumab-Treated Patients with Renal Cell Carcinoma and Gastric Cancer
por: Takada, Shinya, et al.
Publicado: (2022)

Association of probiotic use with nivolumab effectiveness against various cancers: A multicenter retrospective cohort study
por: Arai, Junya, et al.
Publicado: (2023)

Randomised phase II trial of trifluridine/tipiracil (FTD/TPI) plus ramucirumab (RAM) versus trifluridine/tipiracil for previously treated patients with advanced gastric or esophagogastric junction adenocarcinoma (RETRIEVE study, WJOG15822G)
por: Takahashi, Naoki, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_lot9ctvpfmb2uelgndclpai0cc